Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.
| Revenue (Most Recent Fiscal Year) | $266.96M |
| Net Income (Most Recent Fiscal Year) | $28.51M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.47 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 2.75 |
| Pre-Tax Margin (Trailing 12 Months) | 24.88% |
| Net Margin (Trailing 12 Months) | -66.30% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -26.51% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 2.59 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-1.58 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.41 |
| Earnings per Share (Most Recent Fiscal Year) | $0.25 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 115.93M |
| Free Float | 106.57M |
| Market Capitalization | $92.98M |
| Average Volume (Last 20 Days) | 1.48M |
| Beta (Past 60 Months) | 1.01 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 8.08% |
| Percentage Held By Institutions (Latest 13F Reports) | 72.82% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |